Production (Stage)
Akebia Therapeutics, Inc.
AKBA
$2.86
$0.031.06%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 6.11M | -22.80M | -20.04M | -8.58M | -17.99M |
| Total Depreciation and Amortization | 314.00K | 13.54M | 9.37M | 9.41M | 9.38M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 9.71M | 8.03M | 11.63M | 2.75M | 4.33M |
| Change in Net Operating Assets | -29.73M | -3.23M | -7.66M | -13.64M | -15.15M |
| Cash from Operations | -13.59M | -4.47M | -6.70M | -10.07M | -19.43M |
| Capital Expenditure | -18.00K | -2.00K | -2.00K | -29.00K | -- |
| Sale of Property, Plant, and Equipment | 172.00K | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 154.00K | -2.00K | -2.00K | -29.00K | -- |
| Total Debt Issued | 10.00M | 0.00 | 0.00 | 8.00M | 37.00M |
| Total Debt Repaid | -462.00K | 1.00K | 0.00 | -374.00K | -36.73M |
| Issuance of Common Stock | 65.47M | 22.32M | 1.75M | 14.00K | 18.95M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -63.00K | 0.00 | -522.00K | 0.00 | -750.00K |
| Cash from Financing | 74.94M | 22.33M | 1.22M | 7.64M | 18.48M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 61.51M | 17.86M | -5.47M | -2.46M | -957.00K |